A study published in Nature Communications identified blood biomarkers that track cognitive decline across Alzheimer’s disease stages in a community‑based population. The investigators correlated plasma signatures with clinical measures and cognitive staging, enabling less invasive disease monitoring than cerebrospinal fluid or PET imaging. The result advances blood‑based diagnostics for neurodegeneration and could streamline patient selection and longitudinal monitoring in clinical trials.